Literature DB >> 10516071

Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice.

D Nardelli-Haefliger1, R Roden, C Balmelli, A Potts, J Schiller, P De Grandi.   

Abstract

We have recently shown that nasal immunization of anesthetized mice with human papillomavirus type 16 (HPV16) virus-like particles (VLPs) is highly effective at inducing both neutralizing immunoglobulin A (IgA) and IgG in genital secretions, while parenteral immunization induced only neutralizing IgG. Our data also demonstrated that both isotypes are similarly neutralizing according to an in vitro pseudotyped neutralization assay. However, it is known that various amounts of IgA and IgG are produced in genital secretions along the estrous cycle. Therefore, we have investigated how this variation influences the amount of HPV16 neutralizing antibodies induced after immunization with VLPs. We have compared parenteral and nasal protocols of vaccination with daily samplings of genital secretions of mice. Enzyme-linked immunosorbent assay analysis showed that total IgA and IgG inversely varied along the estrous cycle, with the largest amounts of IgA in proestrus-estrus and the largest amount of IgG in diestrus. This resulted in HPV16 neutralizing titers of IgG only being achieved during diestrus upon parenteral immunization. In contrast, nasal vaccination induced neutralizing titers of IgA plus IgG throughout the estrous cycle, as confirmed by in vitro pseudotyped neutralization assays. Our data suggest that mucosal immunization might be more efficient than parenteral immunization at inducing continuous protection of the female genital tract.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516071      PMCID: PMC112997     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract.

Authors:  W S Gallichan; K L Rosenthal
Journal:  Virology       Date:  1996-10-15       Impact factor: 3.616

2.  Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina.

Authors:  C Bergquist; E L Johansson; T Lagergård; J Holmgren; A Rudin
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  Local antibody response to poliovaccine in the human female genital tract.

Authors:  P L Ogra; S S Ogra
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

4.  A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells.

Authors:  J D Sedgwick; P G Holt
Journal:  J Immunol Methods       Date:  1983-02-25       Impact factor: 2.303

5.  A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells.

Authors:  C C Czerkinsky; L A Nilsson; H Nygren; O Ouchterlony; A Tarkowski
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  Immunoglobulins in the mouse uterus during the oestrous cycle.

Authors:  F Rachman; V Casimiri; A Psychoyos; O Bernard
Journal:  J Reprod Fertil       Date:  1983-09

7.  Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

Authors:  D Nardelli-Haefliger; R B Roden; J Benyacoub; R Sahli; J P Kraehenbuhl; J T Schiller; P Lachat; A Potts; P De Grandi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

8.  Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation.

Authors:  W H Kutteh; S J Prince; K R Hammond; C C Kutteh; J Mestecky
Journal:  Clin Exp Immunol       Date:  1996-06       Impact factor: 4.330

9.  Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast.

Authors:  R S Lowe; D R Brown; J T Bryan; J C Cook; H A George; K J Hofmann; W M Hurni; J G Joyce; E D Lehman; H Z Markus; M P Neeper; L D Schultz; A R Shaw; K U Jansen
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

10.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.

Authors:  R B Roden; H L Greenstone; R Kirnbauer; F P Booy; J Jessie; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

View more
  21 in total

Review 1.  Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Authors:  Samir N Khleif
Journal:  Curr Treat Options Oncol       Date:  2003-04

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Monitoring of vaccine-specific gamma interferon induction in genital mucosa of mice by real-time reverse transcription-PCR.

Authors:  Véronique Revaz; Anne Debonneville; Martine Bobst; Denise Nardelli-Haefliger
Journal:  Clin Vaccine Immunol       Date:  2008-03-26

4.  Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen.

Authors:  N K Childers; K L Miller; G Tong; J C Llarena; T Greenway; J T Ulrich; S M Michalek
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.

Authors:  Lissette S Velasquez; Samantha Shira; Alice N Berta; Jacquelyn Kilbourne; Babu M Medi; Ian Tizard; Yawei Ni; Charles J Arntzen; Melissa M Herbst-Kralovetz
Journal:  Vaccine       Date:  2011-06-02       Impact factor: 3.641

Review 6.  How will HPV vaccines affect cervical cancer?

Authors:  Richard Roden; T-C Wu
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

7.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

Review 8.  Human papillomavirus type 16 E5 protein as a therapeutic target.

Authors:  Sang-Woo Kim; Joo-Sung Yang
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

9.  Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.

Authors:  Nicolas Cuburu; Mi-Na Kweon; Catherine Hervouet; Hye-Ran Cha; Yuk-Ying S Pang; Jan Holmgren; Konrad Stadler; John T Schiller; Fabienne Anjuère; Cecil Czerkinsky
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

10.  Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Authors:  Subhashini Jagu; Balasubramanyam Karanam; Ratish Gambhira; Sudha V Chivukula; Revathi J Chaganti; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.